NCT05939648 is a Phase 2 clinical trial of SARS-CoV-2 Bivalent mRNA Vaccine in SARS-CoV-2, sponsored by AIM Vaccine Co., Ltd..

Who is sponsoring NCT05939648?

NCT05939648 is sponsored by AIM Vaccine Co., Ltd..

What drugs are being tested in NCT05939648?

Interventions in NCT05939648: SARS-CoV-2 Bivalent mRNA Vaccine, Saline.

What condition does NCT05939648 study?

NCT05939648 studies SARS-CoV-2.

Is NCT05939648 still recruiting?

NCT05939648 is currently status unknown. Last updated 24 November 2023.

Last reviewed 2023-11-24 · How we verify

NCT05939648

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)

Status unknown Phase 2 Last updated 24 November 2023

What this trial tests

Phase 2 trial testing SARS-CoV-2 Bivalent mRNA Vaccine in SARS-CoV-2 in 450 participants. Status unknown.

Timeline

9 October 2023

Primary endpoint
30 November 2023

30 December 2024

Quick facts

Lead sponsor	AIM Vaccine Co., Ltd.
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	450
Start date	9 October 2023
Primary completion	30 November 2023
Estimated completion	30 December 2024
Sites	1 location across China

Drugs / interventions tested

SARS-CoV-2 Bivalent mRNA Vaccine — full drug profile →
Saline

Conditions studied

SARS-CoV-2 — all drugs for SARS-CoV-2 →

Sponsor

AIM Vaccine Co., Ltd. — full company profile →

Who can join

18 and older, any sex, with SARS-CoV-2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial is a phase II clinical trial of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021). The trial was randomized, blinded, placebo controlled. To evaluate the safety and immunogenicity of the study vaccine in participants aged 18 years and older who have received SARS-CoV-2 Vaccine.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Recent Advances in Messenger Ribonucleic Acid (mRNA) Vaccines and Their Delivery Systems: A Review.
Yihunie W, Nibret G, Aschale Y. · · 2023 · cited 11× · PMID 37554660 · DOI 10.2147/cpaa.s418314

Verify or expand the search:

Other trials of SARS-CoV-2 Bivalent mRNA Vaccine

Trials testing the same drug.

NCT05939596 — A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Bivalent mRNA Vaccine (L · Phase 1 · unknown

Other recruiting trials for SARS-CoV-2

Currently open trials in the same condition.

NCT07266558 — A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without Hig · Phase 4 · recruiting
NCT06684379 — Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm for the Treatment of A · Phase 1, PHASE2 · recruiting
NCT06585241 — A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations · Phase 4 · recruiting
NCT05876377 — Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data · active not recruiting
NCT05799651 — Safety and Immunogenicity of Glycovax-002 Vaccine in Healthy Adults · Phase 1 · active not recruiting

Other AIM Vaccine Co., Ltd. trials

Trials by the same sponsor.

NCT05939596 — A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Bivalent mRNA Vaccine (L · Phase 1 · unknown
NCT05352867 — Clinical Trial of SARS-CoV-2 mRNA Vaccine in Chinese People · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05939648 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AIM Vaccine Co., Ltd.
Last refreshed: 24 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05939648.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing